Epidemiological Study in FRONtoTemporal Dementia

Overview

An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 31, 2022

Detailed Description

Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.

Interventions

  • Diagnostic Test: Genetic Screening
    • Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.

Arms, Groups and Cohorts

  • Participants diagnosed with Frontotemporal Dementia
    • Participants diagnosed with Frontotemporal Dementia

Clinical Trial Outcome Measures

Primary Measures

  • To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants
    • Time Frame: 15 months

Participating in This Clinical Trial

Inclusion Criteria

  • Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian – The participant is aged between 25 to 85 years – The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD

Gender Eligibility: All

Minimum Age: 25 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • CENTOGENE GmbH Rostock
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Peter Bauer, Ph.D, Principal Investigator, Centogene GmbH
  • Overall Contact(s)
    • Jefri Jeya Paul, Ph.D, +49 381 80113 543, Jefri.Paul@centogene.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.